Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7685248
Reference Type
Journal Article
Title
Clinical trials: Evidence and unanswered questions - Hyperlipidaemia
Author(s)
Deanfield, JE; ,
Year
2003
Is Peer Reviewed?
Yes
Journal
Cerebrovascular Diseases
ISSN:
1015-9770
EISSN:
1421-9786
Publisher
KARGER
Location
BASEL
Volume
16
Issue
SUPPL. 3
Page Numbers
25-32
Language
English
PMID
12740553
DOI
10.1159/000070274
Web of Science Id
WOS:000184034500005
URL
https://www.karger.com/Article/FullText/70274
Exit
Abstract
It is now clear that the management of hypercholesterolaemia is important for the reduction of morbidity and mortality caused by cerebrovascular and coronary events. The landmark Scandinavian Simvastatin Survival Study was the first to show conclusively that lipid-lowering therapy with statins reduces the incidence of stroke. Subsequent trials, undertaken in a variety of different patient populations, have confirmed that statin therapy reduces the incidence of stroke by approximately one-third. This important benefit has been observed in men and women, the young and the elderly, and also in subjects with diabetes mellitus. In the recent Heart Protection Study, which recruited 'high-risk' vascular subjects, stroke risk reduction was demonstrated even among those subjects considered to have 'low' low-density lipoprotein (LDL) cholesterol levels. The benefits of statin therapy in stroke have been attributed to reductions in cholesterol and to other non-lipid-lowering effects of statins. Ongoing clinical trials such as TNT (Treating to New Targets) and IDEAL (Incremental Decrease in Endpoints through Aggressive Lipid lowering) will test the 'lower is better' hypothesis. Using statins to lower LDL cholesterol to levels that are below current guidelines will provide additional benefits in stroke risk reduction. Most of the data on cholesterol reduction and cerebrovascular events have been derived from studies of patients with documented coronary heart disease (CHD). The ongoing SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial will examine the benefits of LDL cholesterol lowering in patients with previous stroke or transient ischaemic attack (TIA), but no history of coronary problems. Copyright (C) 2003 S. Karger AG, Basel.
Keywords
Hyperlipidaemia; Low-density lipoprotein cholesterol; Statin therapy
Conference Name
11th European Stroke Conference
Conference Location
GENEVA, SWITZERLAND
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity